

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22610 A1

- (51) International Patent Classification⁷: C07D 413/04, 413/14, 417/14, A61K 31/422, 31/433, 31/439, 31/454, 31/4725, 31/496, 31/497, A61P 35/00
- (74) Agents: GOVINDASWAMY, Nandakumar et al.; Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139-4242 (US).
- (21) International Application Number: PCT/US01/28790
- (22) International Filing Date:
14 September 2001 (14.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/232,956 15 September 2000 (15.09.2000) US
- (71) Applicant (for all designated States except US): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HALE, Michael [US/US]; Vertex Pharmaceuticals Inc., 42 Sunset Road, Bedford, MA 01730 (US). JANETKA, James [US/US]; 32 Washington Street, Beverly, MA 01915 (US). MALTAIS, Francois [CA/US]; 289 Highland Avenue, 301, Somerville, MA 02144 (US). CAO, Jingrong [CN/US]; 45 Madison Avenue, Newton, MA 02460 (US). MASHAL, Robert [US/US]; 95 Prince Street, West Newton, MA 02165 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/22610 A1

(54) Title: ISOXAZOLES AND THEIR USE AS INHIBITORS OF ERK

(57) Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula (I) wherein Ht is an optionally substituted heteroaryl ring selected from pyrrol-3-yl, pyrazol-3-yl, [1,2,3]triazol-4-yl, or tetrazol-5-yl, and A-B is N-O or O-N. The compounds are useful for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

ISOXAZOLES AND THEIR USE AS INHIBITORS OF ERK

FIELD OF THE INVENTION

The present invention is in the field of medicinal chemistry and relates to isoxazole compounds that are protein kinase inhibitors, especially inhibitors of ERK, compositions containing such compounds and
5 methods of use. The compounds are useful for treating cancer and other diseases that are alleviated by protein kinase inhibitors.

BACKGROUND OF THE INVENTION

10 Mammalian mitogen-activated protein (MAP)1 kinases are serine/threonine kinases that mediate intracellular signal transduction pathways (Cobb and Goldsmith, 1995, *J Biol. Chem.* 270, 14843; Davis, 1995, *Mol. Reprod. Dev.* 42, 459). Members of the MAP kinase
15 family share sequence similarity and conserved structural domains, and include the ERK (extracellular signal regulated kinase), JNK (Jun N-terminal kinase) and p38 kinases. JNKs and p38 kinases are activated in response to the pro-inflammatory cytokines TNF-alpha and
20 interleukin-1, and by cellular stress such as heat shock, hyperosmolarity, ultraviolet radiation, lipopolysaccharides and inhibitors of protein synthesis (Derijard et al., 1994, *Cell* 76, 1025; Han et al., 1994, *Science* 265, 808; Raingeaud et al., 1995, *J Biol. Chem.*
25 270, 7420; Shapiro and Dinarello, 1995, *Proc. Natl. Acad. Sci. USA* 92, 12230). In contrast, ERKs are activated by mitogens and growth factors (Bokemeyer et al., 1996, *Kidney Int.* 49, 1187).

ERK2 is a widely distributed protein kinase
30 that achieves maximum activity when both Thr183 and

Tyr185 are phosphorylated by the upstream MAP kinase kinase, MEK1 (Anderson et al., 1990, *Nature* 343, 651; Crews et al., 1992, *Science* 258, 478). Upon activation, ERK2 phosphorylates many regulatory proteins, including
5 the protein kinases Rsk90 (Bjorbaek et al., 1995, *J. Biol. Chem.* 270, 18848) and MAPKAP2 (Rouse et al., 1994, *Cell* 78, 1027), and transcription factors such as ATF2 (Raingeaud et al., 1996, *Mol. Cell Biol.* 16, 1247), Elk-1 (Raingeaud et al. 1996), c-Fos (Chen et al., 1993 *Proc.*
10 *Natl. Acad. Sci. USA* 90, 10952), and c-Myc (Oliver et al., 1995, *Proc. Soc. Exp. Biol. Med.* 210, 162). ERK2 is also a downstream target of the Ras/Raf dependent pathways (Moodie et al., 1993, *Science* 260, 1658) and may help relay the signals from these potentially oncogenic
15 proteins. ERK2 has been shown to play a role in the negative growth control of breast cancer cells (Frey and Mulder, 1997, *Cancer Res.* 57, 628) and hyperexpression of ERK2 in human breast cancer has been reported (Sivaraman et al., 1997, *J Clin. Invest.* 99, 1478). Activated ERK2
20 has also been implicated in the proliferation of endothelin-stimulated airway smooth muscle cells, suggesting a role for this kinase in asthma (Whelchel et al., 1997, *Am. J. Respir. Cell Mol. Biol.* 16, 589).

AKT, also known as protein kinase B, is a
25 serine/threonine kinase that plays a central role in promoting the survival of a wide range of cell types [Khwaja, A., *Nature*, pp. 33-34 (1990)]. It has been shown by Zang, et al, that human ovarian cancer cells display elevated levels of AKT-1 and AKT-2. Inhibition
30 of AKT induces apoptosis of these human ovarian cancer cells which demonstrates that AKT may be an important target for ovarian cancer treatment [Zang, Q. Y., et al, *Oncogene*, 19 (2000)] and other proliferative disorders. The AKT pathway has also been implicated in motoneuronal

survival and nerve regeneration [Kazuhiko, N., et al, *The Journal of Neuroscience*, 20 (2000)].


US patent 5,470,862 discloses an isoxazole compound as an intermediate in the preparation of
5 intravenous anesthetics.

There is a high unmet medical need to develop protein kinase inhibitors, especially ERK and AKT inhibitors especially considering the currently available, relatively inadequate treatment options for
10 the majority of these conditions.

Accordingly, there is still a great need to develop potent inhibitors of protein kinase, including ERK and AKT inhibitors, that are useful in treating various conditions associated with protein kinase
15 activation.

DESCRIPTION OF THE INVENTION

It has now been found that compounds of this invention and pharmaceutical compositions thereof are effective as protein kinase inhibitors, especially as inhibitors of ERK and AKT. These compounds have the
20 general formula I:



I

or a pharmaceutically acceptable derivative or prodrug thereof, wherein:

Ht is a heteroaryl ring selected from pyrrol-3-yl, pyrazol-3-yl, [1,2,4]triazol-3-yl, [1,2,3]triazol-4-yl, or tetrazol-5-yl; said pyrrol-3-yl and pyrazol-3-yl

each having R^3 and QR^4 substituents, and said triazole substituted by either R^3 or QR^4 ;

A-B is N-O or O-N;

R^1 is selected from R^5 , fluorine, $N(R^5)_2$, OR, $NRCOR$, $CON(R^5)_2$, SO_2R , $NRSO_2R$, or $SO_2N(R^5)_2$;

T and Q are each independently selected from a valence bond or a linker group;

each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons;

R^2 is selected from hydrogen, CN, fluorine, or an optionally substituted group selected from aryl, heteroaryl, heterocyclyl, an acyclic aliphatic group having one to six carbons, or a cyclic aliphatic group having four to ten carbons; wherein R^2 has up to one L-W substituent and up to three R^8 substituents;

L is a C_{1-6} alkylidene chain which is optionally substituted, and wherein up to two methylene units of L are optionally replaced by -C(O)-, -C(O)C(O)-, -CONH-, -CONHNH-, -CO₂-, -OC(O)-, -NHCO₂-, -O-, -NHCONH-,
5 -OC(O)NH-, -NHNH-, -NHCO-, -S-, -SO-, -SO₂-, -NH-, -SO₂NH-, -NHSO₂NH-, or -NHSO₂-;

W is selected from R^9 , $CH(R^9)_2$, $CH(R^9)N(R^9)_2$, or $N(R^9)_2$;

R^3 is selected from R, OH, OR, $N(R)_2$, fluorine, or CN;

R^4 is selected from $-R^6$, $-NH_2$, $-NHR^6$, $-N(R^6)_2$, or $-NR^6(CH_2)_yN(R^6)_2$;

each R^5 is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons or two R^5 on the same nitrogen may be taken together with the nitrogen to form a four to eight membered ring having one to three heteroatoms;

each R^6 is independently selected from R^5 , $-(CH_2)_yCH(R^7)_2$,
10 or $-(CH_2)_yR^7$;
y is 0-6;

each R^7 is an optionally substituted group independently
selected from R, aryl, aralkyl, aralkoxy, heteroaryl,
heteroarylalkyl, heteroarylalkoxy, heterocyclyl,
heterocyclylalkyl, heterocyclylalkoxy, hydroxyalkyl,
5 alkoxyalkyl, aryloxyalkyl, or alkoxycarbonyl;
each R^8 is independently selected from halogen, $-R'$, $-OR'$,
 $-SR'$, $-NO_2$, $-CN$, $-N(R^5)_2$, $-NRC(O)R'$, $-NRC(O)N(R^5)_2$,
 $-NRCO_2R'$, $-NRNRC(O)R'$, $-NRNRC(O)N(R^5)_2$, $-NRNRCO_2R'$,
 $-C(O)C(O)R'$, $-C(O)CH_2C(O)R'$, $-CO_2R'$, $-C(O)R'$,
10 $-C(O)N(R^5)_2$, $-OC(O)N(R^5)_2$, $-S(O)_2R'$, $-SO_2N(R^5)_2$, $-S(O)R'$,
 $-NRSO_2N(R^5)_2$, $-NRSO_2R'$, $-C(=S)N(R^5)_2$, or $-C(=NH)N(R^5)_2$;
wherein each R' is independently selected from
hydrogen, or an optionally substituted group selected
from aliphatic, heteroaryl, heterocyclyl, or phenyl;
15 and
each R^9 is independently selected from R^5 , R^8 , or an
optionally substituted group selected from aryl,
aralkyl, aralkoxy, heteroaryl, heteroaralkyl,
heterocyclyl, or heterocyclylalkyl.

20 As used herein, the following definitions shall
apply unless otherwise indicated. In addition, unless
otherwise indicated, functional group radicals are
independently selected.

The term "aliphatic" as used herein means
25 straight-chain, branched or cyclic C_1 - C_{12} hydrocarbons
which are completely saturated or which contain one or
more units of unsaturation but which are not aromatic.
For example, suitable aliphatic groups include
substituted or unsubstituted linear, branched or cyclic
30 alkyl, alkenyl, alkynyl groups and hybrids thereof such
as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or
(cycloalkyl)alkenyl. The terms "alkyl", "alkoxy",
"hydroxyalkyl", "alkoxyalkyl", and "alkoxycarbonyl", used
alone or as part of a larger moiety includes both

straight and branched chains containing one to twelve carbon atoms. The terms "alkenyl" and "alkynyl" used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve
5 carbon atoms. The term "cycloalkyl" used alone or as part of a larger moiety shall include cyclic C₃-C₁₂ hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic.

10 The terms "haloalkyl", "haloalkenyl" and "haloalkoxy" means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br, or I.

The term "heteroatom" means N, O, or S and
15 includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. It also includes =N- and -NR⁺-, wherein R⁺ is as defined infra.

The term "carbocycle", "carbocyclyl", or "carbocyclic" as used herein means an aliphatic ring
20 system having three to fourteen members. The term "carbocycle", "carbocyclyl", or "carbocyclic" whether saturated or partially unsaturated, also refers to rings that are optionally substituted. The terms "carbocyclyl" or "carbocyclic" also include aliphatic rings that are
25 fused to one or more aromatic or nonaromatic rings, such as in a decahydronaphthyl or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring.

The term "aryl" used alone or as part of a
30 larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to aromatic ring groups having five to fourteen members, such as phenyl, benzyl, phenethyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. The term "aryl" also refers to rings that are

optionally substituted. The term "aryl" may be used interchangeably with the term "aryl ring". "Aryl" also includes fused polycyclic aromatic ring systems in which an aromatic ring is fused to one or more rings. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. Also included within the scope of the term "aryl", as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as in a indanyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.

The term "heterocyclic" as used herein includes non-aromatic ring systems having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably five or six, are each replaced by a heteroatom such as N, O, or S. Examples of heterocyclic rings include 3-1H-benzimidazol-2-one, (1-substituted)-2-oxo-benzimidazol-3-yl, 2-tetrahydrofuran-3-yl, 3-tetrahydrofuran-2-yl, 2-tetrahydrothiophen-3-yl, 4-morpholinyl, 2-morpholinyl, 3-morpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-thiomorpholinyl, 2-pyrrolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-piperazinyl, 2-piperazinyl, 3-piperazinyl, 4-piperazinyl, 1-phthalimidinyl, 3-piperidinyl, N-substituted diazolonyl, 1-phthalimidinyl, benzoxanonyl, benzothiolanonyl, and benzothianonyl. Also included within the scope of the term "heterocyclic" or "heterocyclic", as it is used herein, is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic or non-aromatic rings, such as in an indolinyl, chroman-4-yl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of

attachment is on the non-aromatic heteroatom-containing ring. The term "heterocycle", "heterocyclyl", or "heterocyclic" whether saturated or partially unsaturated, also refers to rings that are optionally substituted.

The term "heteroaryl", used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to heteroaromatic ring groups having five to fourteen members. Examples of heteroaryl rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetrazolyl, 2-triazolyl, 5-triazolyl, 2-thienyl, 3-thienyl, carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, benzooxazolyl, benzimidazolyl, isoquinolinyl, indolyl, isoindolyl, acridinyl, or benzoisoxazolyl. Also included within the scope of the term "heteroaryl", as it is used herein, is a group in which a heteroatomic ring is fused to one or more aromatic or nonaromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include tetrahydroquinoline, tetrahydroisoquinoline, and pyrido[3,4-d]pyrimidinyl. The term "heteroaryl" also refers to rings that are optionally substituted. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic".

An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group

may contain one or more substituents. Examples of suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group include a halogen, $-R^o$, $-OR^o$, $-SR^o$, 1,2-methylene-dioxy, 1,2-ethylenedioxy, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, $-O(Ph)$, substituted $-O(Ph)$, $-CH_2(Ph)$, substituted $-CH_2(Ph)$, $-CH_2CH_2(Ph)$, substituted $-CH_2CH_2(Ph)$, $-NO_2$, $-CN$, $-N(R^o)_2$, $-NR^oC(O)R^o$, $-NR^oC(O)N(R^o)_2$, $-NR^oCO_2R^o$, $-NR^oNR^oC(O)R^o$, $-NR^oNR^oC(O)N(R^o)_2$, $-NR^oNR^oCO_2R^o$, $-C(O)C(O)R^o$, $-C(O)CH_2C(O)R^o$, $-CO_2R^o$, $-C(O)R^o$, $-C(O)N(R^o)_2$, $-OC(O)N(R^o)_2$, $-S(O)_2R^o$, $-SO_2N(R^o)_2$, $-S(O)R^o$, $-NR^oSO_2N(R^o)_2$, $-NR^oSO_2R^o$, $-C(=S)N(R^o)_2$, $-C(=NH)-N(R^o)_2$, $-(CH_2)_yNHC(O)R^o$, $-(CH_2)_yNHC(O)CH(V-R^o)(R^o)$; wherein R^o is H, a substituted or unsubstituted aliphatic group, an unsubstituted heteroaryl or heterocyclic ring, phenyl (Ph), substituted Ph, $-O(Ph)$, substituted $-O(Ph)$, $-CH_2(Ph)$, or substituted $-CH_2(Ph)$; y is 0-6; and V is a linker group. Examples of substituents on the aliphatic group or the phenyl ring include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.

An aliphatic group or a non-aromatic heterocyclic ring may contain one or more substituents. Examples of suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring include those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: $=O$, $=S$, $=NNHR^*$, $=NN(R^*)_2$, $=N-$, $=NNHC(O)R^*$, $=NNHCO_2(alkyl)$, $=NNHSO_2(alkyl)$, or $=NR^*$, where each R^* is independently selected from hydrogen, an unsubstituted aliphatic group or a substituted aliphatic group. Examples of

substituents on the aliphatic group include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, 5 nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.

Suitable substituents on the nitrogen of an aromatic or non-aromatic heterocyclic ring include $-R^+$, $-N(R^+)_2$, $-C(O)R^+$, $-CO_2R^+$, $-C(O)C(O)R^+$, $-C(O)CH_2C(O)R^+$, 10 $-SO_2R^+$, $-SO_2N(R^+)_2$, $-C(=S)N(R^+)_2$, $-C(=NH)-N(R^+)_2$, and $-NR^+SO_2R^+$; wherein R^+ is H, an aliphatic group, a substituted aliphatic group, phenyl (Ph), substituted Ph, $-O(Ph)$, substituted $-O(Ph)$, $CH_2(Ph)$, substituted $CH_2(Ph)$, or an unsubstituted heteroaryl or heterocyclic ring.

15 Examples of substituents on the aliphatic group or the phenyl ring include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, 20 alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.

The term "linker group" or "linker" means an organic moiety that connects two parts of a compound. Linkers are typically comprised of an atom such as oxygen 25 or sulfur, a unit such as $-NH-$, $-CH_2-$, $-C(O)-$, $-C(O)NH-$, or a chain of atoms, such as an alkylidene chain. The molecular mass of a linker is typically in the range of about 14 to 200. Examples of linkers include a saturated or unsaturated C_{1-6} alkylidene chain which is optionally 30 substituted, and wherein one or two saturated carbons of the chain are optionally replaced by $-C(O)-$, $-C(O)C(O)-$, $-CONH-$, $-CONHNH-$, $-CO_2-$, $-OC(O)-$, $-NHCO_2-$, $-O-$, $-NHCONH-$, $-OC(O)NH-$, $-NHNH-$, $-NHCO-$, $-S-$, $-SO-$, $-SO_2-$, $-NH-$, $-SO_2NH-$, or $-NHSO_2-$.


The term "alkylidene chain" refers to an optionally substituted, straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation. The optional substituents are as described
5 above for an aliphatic group.

A combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound. A stable compound or chemically feasible compound is one that is
10 not substantially altered when kept at a temperature of 40 °C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.

It will be apparent to one skilled in the art that certain compounds of this invention may exist in
15 tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention.


Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for
20 each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds which
25 differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a ¹³C- or ¹⁴C-enriched carbon are within the
30 scope of this invention.

One embodiment of this invention relates to compounds wherein A-B is N-O, shown by formula II:




II


or a pharmaceutically acceptable derivative or prodrug thereof, wherein R^1 , R^2 , R^3 , R^4 , T , and Q are as described above. Preferred embodiments of formula II are shown below for the Ht ring being pyrrol-3-yl (II-A), pyrazol-3-yl (II-B), [1,2,4]triazol-3-yl (II-C), [1,2,3]triazol-4-yl (II-D), and tetrazol-5-yl (II-E).




II-A




II-B



II-C



II-D



II-E

Preferred compounds of formulae II-A, II-B, II-C, II-D, and II-E include those having one or more, and most preferably all, of the following features: (a) Q is $-CO-$, $-CO_2-$, or $-CONH-$; (b) T is a valence bond, $-NHC(O)-$, or $-NHCH_2-$; (c) R^1 is hydrogen or NHR ; (d) R^2 is an optionally substituted aryl ring, preferably a phenyl ring, and more preferably a phenyl ring having up to one L-W substituent and up to three R^8 substituents; (e) W is selected from R^9 , $CH(R^9)_2$, $CH(R^9)N(R^9)_2$, or $N(R^9)_2$; (f) R^3 is hydrogen; (g) R^4 is selected from $-R^6$, $-NH_2$, $-NHR^6$, $-N(R^6)_2$, or $-NR^6(CH_2)_yN(R^6)_2$; (h) R^6 is R^5 , $-(CH_2)_yCH(R^7)_2$, or

$-(CH_2)_yR^7$; and/or (i) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl.

Preferred R^8 substituents on the R^2 phenyl group include halo, nitro, haloalkyl, hydroxyalkyl, C_{1-6} aliphatic, alkoxy, amino, and heterocyclyl. Examples of preferred L groups include $-CH_2-$, $-CH_2NH-$, $-CH_2NHC(O)-$, $-NH-$, $-CH_2CH_2NH-$, $-CH_2O-$, $-CH_2C(O)NH-$, $-CH_2NHCH_2CH_2NHC(O)-$, and $-CH_2NHC(O)CH_2CH_2NHC(O)-$. Preferred W groups include $-CH(C_{1-6} \text{ aliphatic})NC(O)(C_{1-6} \text{ aliphatic})$, $-CH(CH_2OH)NC(O)(C_{1-6} \text{ aliphatic})$, $-CH(CH_2SH)NC(O)(C_{1-6} \text{ aliphatic})$, $-N(C_{1-6} \text{ aliphatic})_2$, -heterocyclyl (e.g. pyrrolidinyl, morpholinyl, thiomorpholinyl, and piperidinyl), $-CH(C_{1-6} \text{ aliphatic})NH_2$, $-CH(C_{1-6} \text{ aliphatic})NC(O)O(C_{1-6} \text{ aliphatic})$, $-CH_2CN$, and $-CH_2N(C_{1-6} \text{ aliphatic})_2$.

When R^4 is R^6 , preferred R^6 groups include pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, and piperazin-1-yl wherein each group is optionally substituted. When R^4 is $-NHR^6$ or $-N(R^6)_2$, preferred R^6 groups further include $(CH_2)_yR^7$ and $-(CH_2)_yCH(R^7)_2$. Examples of preferred R^6 and R^7 include pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, tetrahydrofuran-2-yl, cyclohexyl, phenyl, $-CH_2OH$, $-(CH_2)_2OH$, and isopropyl, wherein each group is optionally substituted.

Exemplary structures of formula II-A, wherein R^1 and R^3 are each hydrogen, are set forth in Table 1 below.






















Table 1. Compounds of Formula II-A













No.	T-R ²	Q-R ⁴
IIA-1	phenyl	CON(Me) ₂
IIA-2	2-chlorophenyl	CONHCH ₂ (Ph)
IIA-3	2-chlorophenyl	CO(morpholin-4-yl)
IIA-4	4-methoxyphenyl	CONHCH ₂ (pyridin-4-yl)
IIA-5	3-fluorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-6	3-methoxyphenyl	CONHCH ₂ (pyridin-4-yl)
IIA-7	2,5-dimethoxyphenyl	CONHCH ₂ (pyridin-4-yl)
IIA-8	3,4-difluorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-9	2,3-difluorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-10	2,5-difluorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-11	4-methoxyphenyl	CONHCH ₂ (pyridin-3-yl)
IIA-12	3-fluorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-13	3-methoxyphenyl	CONHCH ₂ (pyridin-3-yl)
IIA-14	2,5-dimethoxyphenyl	CONHCH ₂ (pyridin-3-yl)
IIA-15	3,4-difluorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-16	2,3-difluorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-17	2,5-difluorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-18	4-methoxyphenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-19	3-fluorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-20	3-methoxyphenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-21	2,5-dimethoxyphenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-22	3,4-difluorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-23	2,3-difluorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-24	2,5-difluorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-25	4-fluorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-26	4-methoxyphenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-27	3-fluorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-28	3-methoxyphenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-29	2,5-dimethoxyphenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-30	3,4-difluorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-31	2,3-difluorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-32	2,5-difluorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-33	4-fluorophenyl	CO(morpholin-4-yl)
IIA-34	4-methoxyphenyl	CO(morpholin-4-yl)
IIA-35	3-fluorophenyl	CO(morpholin-4-yl)

No.	T-R ²	Q-R ⁴
IIA-36	3-methoxyphenyl	CO(morpholin-4-yl)
IIA-37	2,5-dimethoxyphenyl	CO(morpholin-4-yl)
IIA-38	2,3-difluorophenyl	CO(morpholin-4-yl)
IIA-39	2,5-difluorophenyl	CO(morpholin-4-yl)
IIA-40	4-fluorophenyl	CO(4-Me-piperazin-1-yl)
IIA-41	4-methoxyphenyl	CO(4-Me-piperazin-1-yl)
IIA-42	3-fluorophenyl	CO(4-Me-piperazin-1-yl)
IIA-43	3-methoxyphenyl	CO(4-Me-piperazin-1-yl)
IIA-44	2,5-dimethoxyphenyl	CO(4-Me-piperazin-1-yl)
IIA-45	2,3-difluorophenyl	CO(4-Me-piperazin-1-yl)
IIA-46	2,5-difluorophenyl	CO(4-Me-piperazin-1-yl)
IIA-47	3-chlorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-48	3-chlorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-49	3-chlorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-50	3-chlorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-51	3-chlorophenyl	CO(4-Me-piperazin-1-yl)
IIA-52	4-chlorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-53	4-chlorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-54	4-chlorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-55	4-chlorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-56	4-chlorophenyl	CO(morpholin-4-yl)
IIA-57	4-chlorophenyl	CO(4-Me-piperazin-1-yl)
IIA-58	3,4-dichlorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-59	3,4-dichlorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-60	3,4-dichlorophenyl	CO(morpholin-4-yl)
IIA-61	3,4-dichlorophenyl	CO(4-Me-piperazin-1-yl)
IIA-62	2-F-3-chlorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-63	2-F-3-chlorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-64	2-F-3-chlorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-65	2-F-3-chlorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-66	2-F-3-chlorophenyl	CO(morpholin-4-yl)
IIA-67	2-F-3-chlorophenyl	CO(4-Me-piperazin-1-yl)
IIA-68	3-Cl-4-fluorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-69	3-Cl-4-fluorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-70	3-Cl-4-fluorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-71	3-Cl-4-fluorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)













No.	T-R ²	Q-R ⁴
IIA-72	3-Cl-4-fluorophenyl	CO(morpholin-4-yl)
IIA-73	3-Cl-4-fluorophenyl	CO(4-Me-piperazin-1-yl)
IIA-74	3,4-dimethoxyphenyl	CONHCH ₂ (pyridin-4-yl)
IIA-75	3,4-dimethoxyphenyl	CONHCH ₂ (pyridin-3-yl)
IIA-76	3,4-dimethoxyphenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-77	3,4-dimethoxyphenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-78	3,4-dimethoxyphenyl	CO(morpholin-4-yl)
IIA-79	3,4-dimethoxyphenyl	CO(4-Me-piperazin-1-yl)
IIA-80	4-benzo[1,3]dioxol-5-yl	CONHCH ₂ (pyridin-4-yl)
IIA-81	4-benzo[1,3]dioxol-5-yl	CONHCH ₂ (pyridin-3-yl)
IIA-82	4-benzo[1,3]dioxol-5-yl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-83	4-benzo[1,3]dioxol-5-yl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-84	4-benzo[1,3]dioxol-5-yl	CO(morpholin-4-yl)
IIA-85	4-benzo[1,3]dioxol-5-yl	CO(4-Me-piperazin-1-yl)
IIA-86	3,5-dichlorophenyl	CONHCH ₂ (pyridin-4-yl)
IIA-87	3,5-dichlorophenyl	CONHCH ₂ (pyridin-3-yl)
IIA-88	3,5-dichlorophenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IIA-89	3,5-dichlorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
IIA-90	3,5-dichlorophenyl	CO(morpholin-4-yl)
IIA-91	3,5-dichlorophenyl	CO(4-Me-piperazin-1-yl)
IIA-92	3-Cl-4-SO ₂ NH ₂ -phenyl	CO(morpholin-4-yl)
IIA-93	3-chlorophenyl	CO(morpholin-4-yl)
IIA-94	phenyl	pyridin-4-yl
IIA-95	2-chlorophenyl	morpholin-4-yl
IIA-96	2-chlorophenyl	CH ₂ (morpholin-4-yl)
IIA-97	4-methoxyphenyl	CH ₂ (pyridin-4-yl)
IIA-98		
IIA-99		
IIA-100		













No.	T-R ²	Q-R ⁴
IIA-101		
IIA-102		
IIA-103		
IIA-104		
IIA-105		
IIA-106	phenyl	
IIA-107	phenyl	
IIA-108	3,4-dimethoxyphenyl	
IIA-109	3-chlorophenyl	
IIA-110	3-chlorophenyl	
IIA-111	3-methylphenyl	













No.	T-R ²	Q-R ⁴
IIA-112	3-chlorophenyl	
IIA-113	2-fluoro-3-chlorophenyl	
IIA-114	2-fluoro-3-chlorophenyl	
IIA-115	3-chlorophenyl	
IIA-116	3,4-dimethoxyphenyl	
IIA-117	3,4-dimethoxyphenyl	
IIA-118	3,4-dimethoxyphenyl	
IIA-119	3-methylphenyl	
IIA-120	2-fluoro-3-chlorophenyl	
IIA-121	2-fluoro-3-chlorophenyl	
IIA-122	2-fluoro-3-chlorophenyl	
IIA-123	3-chlorophenyl	

No.	T-R ²	Q-R ⁴
IIA-124	3,4-dimethoxyphenyl	
IIA-125	2-fluoro-3-chlorophenyl	
IIA-126	2-fluoro-3-chlorophenyl	
IIA-127	3,4-dimethoxyphenyl	
IIA-128	3,5-dichlorophenyl	
IIA-129	3,5-dichlorophenyl	
IIA-130	phenyl	
IIA-131	phenyl	
IIA-132	phenyl	
IIA-133	phenyl	
IIA-134	phenyl	
IIA-135	3,4-dimethoxyphenyl	

No.	T-R ²	Q-R ⁴
IIA-136	3,4-dimethoxyphenyl	
IIA-137	3,4-dimethoxyphenyl	
IIA-138	3-methylphenyl	
IIA-139	3-methylphenyl	
IIA-140	3-methylphenyl	
IIA-141	2-fluoro,3-chlorophenyl	
IIA-142	3-chlorophenyl	
IIA-143	3-chlorophenyl	
IIA-144	3-chlorophenyl	
IIA-145	3-chlorophenyl	
IIA-146	3-chlorophenyl	
IIA-147	phenyl	
IIA-148	phenyl	


No.	T-R ²	Q-R ⁴
IIA-149	3,4-dimethoxyphenyl	
IIA-150	3,4-dimethoxyphenyl	
IIA-151	3-methylphenyl	
IIA-152	3-methylphenyl	
IIA-153	phenyl	
IIA-154	phenyl	
IIA-155	phenyl	
IIA-156	3,4-dimethoxyphenyl	
IIA-157	3,4-dimethoxyphenyl	
IIA-158	3-methylphenyl	
IIA-159	3-methylphenyl	
IIA-160	3-chlorophenyl	

No.	T-R ²	Q-R ⁴
IIA-161	phenyl	
IIA-162	3-chlorophenyl	
IIA-163	3,4-dimethoxyphenyl	
IIA-164	3-chlorophenyl	
IIA-165	phenyl	
IIA-166	phenyl	
IIA-167	phenyl	
IIA-168	3,4-dimethoxyphenyl	
IIA-169	3,4-dimethoxyphenyl	
IIA-170	3,4-dimethoxyphenyl	
IIA-171	3-methylphenyl	
IIA-172	3-methylphenyl	

No.	T-R ²	Q-R ⁴
IIA-173	3-methylphenyl	
IIA-174	3-methylphenyl	
IIA-175	3-methylphenyl	
IIA-176	3-methylphenyl	
IIA-177	2-fluoro,3-chlorophenyl	
IIA-178	2-fluoro,3-chlorophenyl	
IIA-179	2-fluoro,3-chlorophenyl	
IIA-180	2-fluoro,3-chlorophenyl	
IIA-181	phenyl	
IIA-182	3-chlorophenyl	
IIA-183	3-chlorophenyl	
IIA-184	3-chlorophenyl	


No.	T-R ²	Q-R ⁴
IIA-185	3-chlorophenyl	
IIA-186	3-chlorophenyl	
IIA-187	3-methylphenyl	
IIA-188	3-methylphenyl	
IIA-189	2-fluoro,3-chlorophenyl	
IIA-190	2-fluoro,3-chlorophenyl	
IIA-191	phenyl	
IIA-192	3,4-dimethoxyphenyl	
IIA-193	3-methylphenyl	
IIA-194	phenyl	

Another embodiment of this invention relates to compounds wherein A-B is O-N, shown by formula III:




III


or a pharmaceutically acceptable derivative or prodrug thereof, wherein R^1 , R^2 , T, and Q are as described above. Preferred embodiments of formula III are shown below for the Ht ring being pyrrol-3-yl (III-A), pyrazol-3-yl (III-B), [1,2,4]triazol-3-yl (III-C), [1,2,3]triazol-4-yl (III-D), and tetrazol-5-yl (III-E).




III-A




III-B



III-C



III-D



III-E


- Preferred compounds of formulae III-A, III-B, III-C, III-D, and III-E include those having one or more, and most preferably all, of the following features: (a) Q is -CO-, -CO₂-, or -CONH-; (b) T is a valence bond, -NHC(O)-, or -NHCH₂-; (c) R^1 is hydrogen or NHR; (d) R^2 is an optionally substituted aryl ring, preferably a phenyl ring, and more preferably a phenyl ring having up to one L-W substituent and up to three R^8 substituents; (e) W is selected from R^9 , $CH(R^9)_2$, $CH(R^9)N(R^9)_2$, or $N(R^9)_2$; (f) R^3 is hydrogen; (g) R^4 is selected from - R^6 , -NH₂, -NHR⁶, -N(R^6)₂, or -NR⁶(CH₂)_yN(R^6)₂; (h) R^6 is R^5 , -(CH₂)_yCH(R^7)₂, or

$-(CH_2)_yR^7$; and/or (i) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl.

Preferred R^8 substituents of the R^2 phenyl group, if present, include halo, nitro, haloalkyl, hydroxyalkyl, C_{1-6} aliphatic, alkoxy, amino, and heterocyclyl. Preferred L groups include $-CH_2-$, $-CH_2NH-$, $-CH_2NHC(O)-$, $-NH-$, $-CH_2CH_2NH-$, $-CH_2O-$, $-CH_2C(O)NH-$, $-CH_2NHCH_2CH_2NHC(O)-$, and $-CH_2NHC(O)CH_2CH_2NHC(O)-$. Preferred W groups include $-CH(C_{1-6} \text{ aliphatic})NC(O)(C_{1-6} \text{ aliphatic})$, $-CH(CH_2OH)NC(O)(C_{1-6} \text{ aliphatic})$, $-CH(CH_2SH)NC(O)(C_{1-6} \text{ aliphatic})$, $N(C_{1-6} \text{ aliphatic})_2$, heterocyclyl (e.g. pyrrolidinyl, morpholinyl, thiomorpholinyl, and piperidinyl), $-CH(C_{1-6} \text{ aliphatic})NH_2$, $-CH(C_{1-6} \text{ aliphatic})NC(O)O(C_{1-6} \text{ aliphatic})$, $-CH_2CN$, and $-CH_2N(C_{1-6} \text{ aliphatic})_2$.

When R^4 is R^6 , preferred R^6 groups include pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, and piperazin-1-yl wherein each group is optionally substituted. When R^4 is $-NHR^6$ or $-N(R^6)_2$, preferred R^6 groups further include $(CH_2)_yR^7$ and $-(CH_2)_yCH(R^7)_2$. Examples of preferred R^6 and R^7 include pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, tetrahydrofuran-2-yl, cyclohexyl, phenyl, $-CH_2OH$, $-(CH_2)_2OH$, and isopropyl, wherein each group is optionally substituted.

Exemplary structures of formula III-A, wherein R^1 and R^3 are each hydrogen, are set forth in Table 2 below.




III-A

Table 2. Compounds of Formula III-A


No.	T-R ²	Q-R ⁴
III-A-1	phenyl	CON(Me) ₂
III-A-2	2-chlorophenyl	CONHCH ₂ (Ph)
III-A-3	2-chlorophenyl	CO(morpholin-4-yl)
III-A-4	4-methoxyphenyl	CONHCH ₂ (pyridin-4-yl)
III-A-5	3-fluorophenyl	CONHCH ₂ (pyridin-4-yl)
III-A-6	3-methoxyphenyl	CONHCH ₂ (pyridin-4-yl)
III-A-7	2,5-dimethoxyphenyl	CONHCH ₂ (pyridin-4-yl)
III-A-8	3,4-difluorophenyl	CONHCH ₂ (pyridin-4-yl)
III-A-9	2,3-difluorophenyl	CONHCH ₂ (pyridin-4-yl)
III-A-10	2,5-difluorophenyl	CONHCH ₂ (pyridin-4-yl)
III-A-11	4-methoxyphenyl	CONHCH ₂ (pyridin-3-yl)
III-A-12	3-fluorophenyl	CONHCH ₂ (pyridin-3-yl)
III-A-13	3-methoxyphenyl	CONHCH ₂ (pyridin-3-yl)
III-A-14	2,5-dimethoxyphenyl	CONHCH ₂ (pyridin-3-yl)
III-A-15	3,4-difluorophenyl	CONHCH ₂ (pyridin-3-yl)
III-A-16	2,3-difluorophenyl	CONHCH ₂ (pyridin-3-yl)
III-A-17	2,5-difluorophenyl	CONHCH ₂ (pyridin-3-yl)
III-A-18	4-methoxyphenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
III-A-19	2,5-difluorophenyl	CONHCH ₂ (1-Et-pyrrolidin-2-yl)
III-A-20	4-fluorophenyl	CO(morpholin-4-yl)
III-A-21	4-fluorophenyl	CO(4-Me-piperazin-1-yl)

According to another embodiment, the present invention relates to compounds of formula IV:




IV


or a pharmaceutically acceptable derivative or prodrug thereof, wherein R^1 , R^2 , T, and Q are as described above. Preferred embodiments of formula IV are shown below for the Ht ring being pyrrol-3-yl (IV-A), pyrazol-3-yl (IV-B), [1,2,4]triazol-3-yl (IV-C), [1,2,3]triazol-4-yl (IV-D), and tetrazol-5-yl (IV-E).




IV-A




IV-B



IV-C



IV-D



IV-E


Preferred compounds of formulae IV-A, IV-B, IV-C, IV-D, and IV-E include those having one or more, and most preferably all, of the following features: (a) Q is -CO-, -CO₂-, or -CONH-; (b) T is a valence bond, -NHC(O)-, or -NHCH₂-; (c) R^2 is an optionally substituted aryl ring, more preferably a phenyl ring having up to one L-W substituent and up to three R^8 substituents; (d) R^3 is hydrogen; (e) R^4 is selected from - R^6 , -NH₂, -NHR⁶,

$-N(R^6)_2$, or $-NR^6(CH_2)_yN(R^6)_2$; (f) R^6 is R^5 , $-(CH_2)_yCH(R^7)_2$, or $-(CH_2)_yR^7$; and/or (g) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group.

Preferred R^8 substituents of the R^2 phenyl group, if present, include halo, nitro, haloalkyl, hydroxyalkyl, C_{1-6} aliphatic, alkoxy, amino, and heterocyclyl.

When R^4 is R^6 , preferred R^6 groups include pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, and piperazin-1-yl wherein each group is optionally substituted. When R^4 is $-NHR^6$ or $-N(R^6)_2$, preferred R^6 groups further include $(CH_2)_yR^7$ and $-(CH_2)_yCH(R^7)_2$. Examples of preferred R^6 and R^7 include pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, tetrahydrofuran-2-yl, cyclohexyl, phenyl, $-CH_2OH$, $-(CH_2)_2OH$, and isopropyl, wherein each group is optionally substituted.










Exemplary structures of formula IV-A, wherein R^3 is hydrogen, are set forth in Table 3 below.




IV-A

Table 3. Compounds IV-A


No.	R	T-R ²	Q-R ⁴
IVA-1	H	phenyl	CON(Me) ₂
IVA-2	H	phenyl	CO ₂ Et
IVA-3	H	3-NO ₂ -phenyl	CONHNH ₂
IVA-4	H	phenyl	CO(pyrrolidin-1-yl)
IVA-5	Me	phenyl	CONHCH ₂ (Ph)
IVA-6	H	3-NO ₂ -phenyl	CO ₂ Et
IVA-7	H	4-Cl-phenyl	CO ₂ Et
IVA-8	Me	4-OMe-phenyl	CO ₂ Et
IVA-9	H	3-NH ₂ -phenyl	CO ₂ Et
IVA-10	H	3-OMe-phenyl	CO ₂ Et

No.	R	T-R ²	Q-R ⁴
IVA-11	H	4-F-phenyl	CO ₂ Et
IVA-12	H	4-NO ₂ -phenyl	CO ₂ Et
IVA-13	Et	3-Cl-phenyl	CO ₂ Et
IVA-14	H	3-F-phenyl	CO ₂ Et
IVA-15	H	phenyl	CO ₂ H
IVA-16	Me	3-Cl-phenyl	CONHCH ₂ (pyridin-4-yl)
IVA-17	H	5-Cl-phenyl	
IVA-18	H	5-F-phenyl	CONHCH ₂ (tetrahydrofuran-2-yl)
IVA-19	Me	5,6-F ₂ -phenyl	CO(4-Me-piperidin-1-yl)
IVA-20	H	4-Cl-phenyl	CONHCH ₂ (pyrid-4-yl)
IVA-21	H	4,5-(OMe) ₂ -phenyl	
IVA-22	Me	4,5-Cl ₂ -phenyl	
IVA-23	H	3-Cl-phenyl	
IVA-24	H	3-Cl-phenyl	
IVA-25	Me	3,5-Cl ₂ -phenyl	
IVA-26	H		
IVA-27	H		CON(Me) ₂

According to another embodiment, the present invention relates to compounds, wherein T is a valence bond and R² is a phenyl ring substituted with L-W and up to three R⁸, of formula V:



or a pharmaceutically acceptable derivative or prodrug thereof, wherein R, R¹, R³, R⁴, R⁸, L, and W are as described above. Preferred embodiments are shown below for the Ht ring being pyrrol-3-yl (V-A), pyrazol-3-yl (V-B), [1,2,4]triazol-3-yl (V-C), [1,2,3]triazol-4-yl (V-D), and tetrazol-5-yl (V-E).



Preferred compounds of formulae V-A, V-B, V-C, V-D, and tetrazol-5-yl V-E include those having one or more, and most preferably all, of the following features:

(a) Q is -CO-, -CO₂-, or -CONH-; (b) R¹ is hydrogen or NHR; (c) W is selected from R⁹, CH(R⁹)₂, CH(R⁹)N(R⁹)₂, or N(R⁹)₂; (d) R³ is hydrogen; (e) R⁸, if present, is halogen, -R', -OR', -SR', -NO₂, -CN, or -N(R⁵)₂; (f) R⁴ is selected

from $-R^6$, $-NH_2$, $-NHR^6$, $-N(R^6)_2$, or $-NR^6(CH_2)_yN(R^6)_2$; (g) R^6 is R^5 , $-(CH_2)_yCH(R^7)_2$, or $-(CH_2)_yR^7$; and/or (h) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl,

5 heterocyclylalkyl group.


Preferred R^8 substituents of the R^2 phenyl group include halo, nitro, haloalkyl, hydroxyalkyl, C_{1-6} aliphatic, alkoxy, amino, and heterocyclyl.

Preferred L groups include $-CH_2-$, $-CH_2NH-$, $-CH_2NHC(O)-$, $-NH-$, $-CH_2CH_2NH-$, $-CH_2O-$, $-CH_2C(O)NH-$, $-CH_2NHCH_2CH_2NHC(O)-$, and $-CH_2NHC(O)CH_2CH_2NHC(O)-$.

Preferred W groups include $-CH(C_{1-6}$ aliphatic) $NC(O)(C_{1-6}$ aliphatic), $-CH(CH_2OH)NC(O)(C_{1-6}$ aliphatic), $-CH(CH_2SH)NC(O)(C_{1-6}$ aliphatic), $N(C_{1-6}$ aliphatic) $_2$, heterocyclyl (e.g. pyrrolidinyl, morpholinyl, thiomorpholinyl, and piperidinyl), $-CH(C_{1-6}$ aliphatic) NH_2 , $-CH(C_{1-6}$ aliphatic) $NC(O)O(C_{1-6}$ aliphatic), $-CH_2CN$, and $-CH_2N(C_{1-6}$ aliphatic) $_2$.

When R^4 is R^6 , preferred R^6 groups include pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, and piperazin-1-yl wherein each group is optionally substituted. When R^4 is $-NHR^6$ or $-N(R^6)_2$, preferred R^6 groups further include $(CH_2)_yR^7$ and $-(CH_2)_yCH(R^7)_2$. Examples of preferred R^6 and R^7 include pyridin-3-yl, pyridin-4-yl, imidazolyl, furan-2-yl, tetrahydrofuran-2-yl, cyclohexyl, phenyl, $-CH_2OH$, $-(CH_2)_2OH$, and isopropyl, wherein each group is optionally substituted.



















Exemplary structures of formula V-A, wherein R^3 is hydrogen and T is a valence bond, are set forth in Table 4 below.



V-A

Table 4. Compounds of Formula V-A

No.	R ¹	R ²	Q-R ⁴
VA-1	H		CON(Me) ₂
VA-2	H		CO ₂ Et
VA-3	H		CONHNH ₂
VA-4	NHMe		
VA-5	NHMe		
VA-6	NHMe		
VA-7	NHEt		CONHCH ₂ (tetrahydrofuran-2-yl)
VA-8	NHMe		CO(4-Me-piperidin-1-yl)
VA-9	H		CONHCH ₂ (pyrid-4-yl)

No.	R ¹	R ²	Q-R ⁴
VA-10	H		
VA-11	H		
VA-12	H		
VA-13	H		
VA-14	H		
VA-15	NH ₂		CONHPh
VA-16	NH ₂		CONHCH ₂ (pyrid-4-yl)
VA-17	NH ₂		
VA-18	NH ₂		
VA-19	H		

No.	R ¹	R ²	Q-R ⁴
VA-20	H		
VA-21	H		
VA-22	Me		
VA-23	H		


The present compounds may be prepared in general by methods known to those skilled in the art for analogous compounds, as illustrated by the general Schemes I, II, III, and IV below. These schemes are illustrated for the pyrrole compounds of this invention and, by analogy, are applicable for the preparation of compounds having the other Ht rings.

10

15

20

Scheme I



Reagents and conditions: (a) PhCH₂COCl, AlCl₃, CH₂Cl₂, 15 minutes, room temperature (b) DMF, 24 hrs, room temperature (c) (Me₂N)₂CH-Ot-Bu, THF, 48 hrs, room temperature (d) H₂N-OH·HCl, K₂CO₃, EtOH, 12 hrs, reflux

An array of compounds of formula II-A are prepared in the following manner, as shown in Scheme I above. In step (a), a series of separate Friedel-Crafts intermediates 2 are prepared from 2-trichloroacetyl pyrrole (1) by treating a concentrated solution of the pyrrole and the appropriate acyl chloride with AlCl₃ in dichloroethane at 25°C. After 1 hour, the resulting slurry is purified by chromatography to afford compounds of formula 2.

In step (b), each compound 2 is first dissolved in DMF. A separate solution of 1.2 equivalents of each of six amines 3 in DMF is also prepared. Using a Bohden parallel synthesizer, each compound 2 is treated with each amine 3. The reactions are performed at ambient temperature for 24 hours then concentrated *in vacuo* to afford compounds of formula 4.


In step (c), the concentrates of compound 4 are dissolved in THF. Using the Bohden parallel synthesizer, each compound 4 is then treated with a solution of

(Me₂N)₂CHO-t-Bu in THF. The resulting mixtures are again stirred at ambient temperature for 48 hours then concentrated *in vacuo* to afford compounds of formula 5.

In step (d), the concentrates of compound 5 are first dissolved in ethanol. Using the Bohden parallel synthesizer, each compound 5 is treated with K₂CO₃ and H₂NOH·HCl. The resulting mixtures are stirred under reflux for 12 hours then concentrated *in vacuo* to afford compounds of formula 6.


Each compound is purified by preparatory HPLC (Gilson) on a C18 reverse-phase column eluted with a gradient of 10-90% MeCN (0.1% TFA) in water over 15 minutes. The details of the conditions used to prepare the compounds as described in Scheme I are set forth in the Examples.

Scheme II



As shown in Scheme II above using the preparation of compound IIIA-22 as an example, compounds of formula III-A may be prepared according to the methods of Zohdi, et al, J. Chem. Res., Synop (1991) 11, pp 322-323.

Scheme III




Reagents and conditions: (a) potassium phthalimide (b) Brederick's reagent (c) hydroxylamine (d) $\text{H}_2\text{N}-\text{OH}\cdot\text{HCl}$, K_2CO_3 , EtOH, 12 hrs, reflux (e) benzyl bromide (f) benzoyl chloride

Scheme III above depicts a general method for preparing compounds of formula I wherein T is NH_2 , NH_2CH_2 , or $\text{NH}_2\text{C(O)}$. In step (a), the bromoacetyl compound **9** is treated with potassium phthalimide to form the protected amino compound **10**. Compound **10** is then treated with Brederick's reagent to form the enaminone compound **11**. In step (c), the enaminone **11** is condensed with hydroxylamine to form the isoxazole compounds which is treated with hydrazine in step (d) to remove the phthalimide protecting group to afford the amino compound **12**. The amino compound **12** may be derivatised with a variety of reagents to afford various compounds of formula I wherein T is other than a valence bond. For example, compound **12** is treated with a benzyl bromide derivative in step (e) to afford the benzylamine compound

13. In step (f), the amino compound 12 is treated with a benzoyl chloride derivative to afford the benzamide compound 14. Other compounds of formula I wherein T is other than a valence bond may be prepared by methods substantially similar to those shown in Scheme III above by modifications of which are well known to those skilled in the art.


Scheme IV



- 10 Reagents and conditions: (a) 3-Cl-4-(R⁹)₂aminomethyl-PhCH₂COC₂H₅, AlCl₃, CH₂Cl₂, 2 hours, RT (b) DMF, 24 hrs, room temperature (c) (Me₂N)₂-Ot-Bu, THF, 24 hrs, room temperature (d) H₂N-OH·HCl, K₂CO₃, EtOH, 12 hrs, reflux

- 15 Scheme IV above shows a general synthetic route that may be used for preparing compounds of formula V-A. These compounds may be prepared by methods substantially similar to those described in Scheme I above.

- 20 According to another embodiment, the invention provides a method of inhibiting ERK or AKT kinase activity in a biological sample. This method comprises the step of contacting said biological sample with a compound of formula I:



I

or a pharmaceutically acceptable derivative or prodrug thereof, wherein:

Ht is a heteroaryl ring selected from pyrrol-3-yl, pyrazol-3-yl, [1,2,4]triazol-3-yl, [1,2,3]triazol-4-yl, or tetrazol-5-yl; said pyrrol-3-yl and pyrazol-3-yl each having R³ and QR⁴ substituents, and said triazole substituted by either R³ or QR⁴;

A-B is N-O or O-N;

R¹ is selected from R⁵, fluorine, N(R⁵)₂, OR, NRCOR, CON(R⁵)₂, SO₂R, NRSO₂R, or SO₂N(R⁵)₂;

T and Q are each independently selected from a valence bond or a linker group;

each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons;

R² is selected from hydrogen, CN, fluorine, or an optionally substituted group selected from aryl, heteroaryl, heterocyclyl, an acyclic aliphatic group having one to six carbons, or a cyclic aliphatic group having four to ten carbons; wherein R² has up to one L-W substituent and up to three R⁸ substituents;

L is a C₁₋₆ alkylidene chain which is optionally substituted, and wherein up to two methylene units of L are optionally replaced by -C(O)-, -C(O)C(O)-, -CONH-, -CONHNH-, -CO₂-, -OC(O)-, -NHCO₂-, -O-, -NHCONH-, -OC(O)NH-, -NHNH-, -NHCO-, -S-, -SO-, -SO₂-, -NH-, -SO₂NH-, -NHSO₂NH-, or -NHSO₂-;

W is selected from R⁹, CH(R⁹)₂, CH(R⁹)N(R⁹)₂, or N(R⁹)₂;

R^3 is selected from R, OH, OR, $N(R)_2$, fluorine, or CN;

R^4 is selected from $-R^6$, $-NH_2$, $-NHR^6$, $-N(R^6)_2$, or
 $-NR^6(CH_2)_yN(R^6)_2$;

each R^5 is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons or two R^5 on the same nitrogen may be taken together with the nitrogen to form a four to eight membered ring having one to three heteroatoms;

each R^6 is independently selected from R^5 , $-(CH_2)_yCH(R^7)_2$, or $-(CH_2)_yR^7$;

5 y is 0-6;

each R^7 is an optionally substituted group independently selected from R, aryl, aralkyl, aralkoxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, or alkoxycarbonyl;

10 each R^8 is independently selected from halogen, $-R'$, $-OR'$, $-SR'$, $-NO_2$, $-CN$, $-N(R^5)_2$, $-NRC(O)R'$, $-NRC(O)N(R^5)_2$, $-NRNRCO_2R'$, $-NRNRC(O)R'$, $-NRNRC(O)N(R^5)_2$, $-NRNRCO_2R'$, $-C(O)C(O)R'$, $-C(O)CH_2C(O)R'$, $-CO_2R'$, $-C(O)R'$,
15 $-C(O)N(R^5)_2$, $-OC(O)N(R^5)_2$, $-S(O)_2R'$, $-SO_2N(R^5)_2$, $-S(O)R'$, $-NRSO_2N(R^5)_2$, $-NRSO_2R'$, $-C(=S)N(R^5)_2$, or $-C(=NH)N(R^5)_2$;

wherein each R' is independently selected from hydrogen, or an optionally substituted group selected from aliphatic, heteroaryl, heterocyclyl, or phenyl;

20 and


each R^9 is independently selected from R^5 , R^8 , or an optionally substituted group selected from aryl, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl.

25 According to a preferred embodiment, the invention relates to a method of inhibiting ERK or AKT kinase activity in a biological sample comprising the step of contacting said biological sample with a compound

of formula formula II, III, IV, or V; more preferably with a compound of formula II-A, III-A, IV-A, or V-A; and most preferably, with a compound listed in Tables 1-4.

The term "biological sample", as used herein
 5 includes cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

Another aspect of this invention relates to a
 10 method for treating a disease in a patient that is alleviated by treatment with an ERK or AKT protein kinase inhibitor, which method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:



I

or a pharmaceutically acceptable derivative or prodrug thereof, wherein:

Ht is a heteroaryl ring selected from pyrrol-3-yl, pyrazol-3-yl, [1,2,4]triazol-3-yl, [1,2,3]triazol-4-yl, or tetrazol-5-yl; said pyrrol-3-yl and pyrazol-3-yl each having R³ and QR⁴ substituents, and said triazole substituted by either R³ or QR⁴;

A-B is N-O or O-N;

R¹ is selected from R⁵, fluorine, N(R⁵)₂, OR, NRCOR, CON(R⁵)₂, SO₂R, NRSO₂R, or SO₂N(R⁵)₂;

T and Q are each independently selected from a valence bond or a linker group;

each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons;

R² is selected from hydrogen, CN, fluorine, or an optionally substituted group selected from aryl, heteroaryl, heterocyclyl, an acyclic aliphatic group having one to six carbons, or a cyclic aliphatic group having four to ten carbons; wherein R² has up to one L-W substituent and up to three R⁸ substituents;

L is a C₁₋₆ alkylidene chain which is optionally substituted, and wherein up to two methylene units of L are optionally replaced by -C(O)-, -C(O)C(O)-, -CONH-, -CONHNH-, -CO₂-, -OC(O)-, -NHCO₂-, -O-, -NHCONH-,
 5 -OC(O)NH-, -NHNH-, -NHCO-, -S-, -SO-, -SO₂-, -NH-,
 -SO₂NH-, -NHSO₂NH-, or -NHSO₂-;

W is selected from R⁹, CH(R⁹)₂, CH(R⁹)N(R⁹)₂, or N(R⁹)₂;

R³ is selected from R, OH, OR, N(R)₂, fluorine, or CN;

R⁴ is selected from -R⁶, -NH₂, -NHR⁶, -N(R⁶)₂, or
 -NR⁶(CH₂)_yN(R⁶)₂;

each R⁵ is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons or two R⁵ on the same nitrogen may be taken together with the nitrogen to form a four to eight membered ring having one to three heteroatoms;

each R⁶ is independently selected from R⁵, -(CH₂)_yCH(R⁷)₂,
 10 or -(CH₂)_yR⁷;

y is 0-6;

each R⁷ is an optionally substituted group independently selected from R, aryl, aralkyl, aralkoxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, heterocyclyl,
 15 heterocyclylalkyl, heterocyclylalkoxy, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, or alkoxycarbonyl;

each R⁸ is independently selected from halogen, -R', -OR', -SR', -NO₂, -CN, -N(R⁵)₂, -NRC(O)R', -NRC(O)N(R⁵)₂,

-NR₂CO₂R', -NRNRC(O)R', -NRNRC(O)N(R⁵)₂, -NRNRCO₂R',
-C(O)C(O)R', -C(O)CH₂C(O)R', -CO₂R', -C(O)R',
-C(O)N(R⁵)₂, -OC(O)N(R⁵)₂, -S(O)₂R', -SO₂N(R⁵)₂, -S(O)R',
-NRSO₂N(R⁵)₂, -NRSO₂R', -C(=S)N(R⁵)₂, or -C(=NH)N(R⁵)₂;

5 wherein each R' is independently selected from
hydrogen, or an optionally substituted group selected
from aliphatic, heteroaryl, heterocyclyl, or phenyl;
and

each R⁹ is independently selected from R⁵, R⁸, or an
10 optionally substituted group selected from aryl,
aralkyl, aralkoxy, heteroaryl, heteroaralkyl,
heterocyclyl, or heterocyclylalkyl.

A preferred embodiment comprises administering
a compound of formula II, III, IV, or V, more preferably
15 a compound of formula II-A, III-A, IV-A, or V-A, and most
preferably, a compound listed in Tables 1-4.

Pharmaceutical compositions useful for such
methods are described below and are another aspect of the
present invention.

20 The present method is especially useful for
treating a disease that is alleviated by the use of an
inhibitor of ERK.

The activity of the compounds as protein kinase
inhibitors, for example as ERK inhibitors, may be assayed
25 *in vitro*, *in vivo* or in a cell line. Using ERK as an
example, *in vitro* assays include assays that determine
inhibition of either the kinase activity or ATPase
activity of activated ERK. Alternate *in vitro* assays
quantitate the ability of the inhibitor to bind to ERK
30 and may be measured either by radiolabelling the
inhibitor prior to binding, isolating the inhibitor/ERK
complex and determining the amount of radiolabel bound,
or by running a competition experiment where new
inhibitors are incubated with ERK bound to known

radioligands. One may use any type or isoform of ERK, depending upon which ERK type or isoform is to be inhibited.

The protein kinase inhibitors of this invention, or pharmaceutical salts thereof, may be formulated into pharmaceutical compositions for administration to animals or humans. These pharmaceutical compositions effective to treat or prevent a protein kinase-mediated condition which comprise the protein kinase inhibitor in an amount sufficient to measurably inhibit protein kinase activity (e.g., ERK or AKT activity) and a pharmaceutically acceptable carrier, are another embodiment of the present invention. The term "measurably inhibit", as used herein means a measurable change in activity between a sample containing said inhibitor and a sample containing only protein kinase.

The compounds of this invention are inhibitors
5 of ERK and AKT kinase as determined by enzymatic assay. The details of the conditions used for the enzymatic assays are set forth in the Examples hereinbelow. Accordingly, these compounds are useful for treating ERK- or AKT-mediated diseases or conditions.

10 The term "ERK-mediated disease" or "condition", as used herein means any disease or other deleterious condition in which ERK is known to play a role. Such conditions include, without limitation, cancer, stroke, diabetes, hepatomegaly, cardiovascular disease including
15 cardiomegaly, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders including asthma, inflammation, neurological disorders and hormone-related diseases. The term "cancer" includes, but is not
20 limited to the following cancers: breast, ovary, cervix,

prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia.

The term "AKT-mediated disease" or "condition", as used herein, means any disease or other deleterious condition in which AKT is known to play a role. AKT-mediated diseases or conditions include, but are not limited to, proliferative disorders, cancer, and neurodegenerative disorders.

In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the above-identified disorders.

A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a

mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system)
5 relative to the parent species.

Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.

10 Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include
15 acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride,
20 hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate,
25 sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically
30 acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and $N^+(C_{1-4} \text{ alkyl})_4$ salts. This invention also envisions the quaternization

of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

The compositions of the present invention may
5 be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial,
10 intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.

Sterile injectable forms of the compositions of
15 this invention may be aqueous or an oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile

injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active

ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions
5 of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt
10 in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs
15 readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal
20 tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment
25 containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol,
30 polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable

carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

5 For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as
10 benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

 The pharmaceutical compositions of this invention may also be administered by nasal aerosol or
15 inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability,
20 fluorocarbons, and/or other conventional solubilizing or dispersing agents.

 The amount of ERK or AKT inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated,
25 the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between about 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.

30 It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of

administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of inhibitor will also depend upon the particular compound
5 in the composition.

The kinase inhibitors of this invention or pharmaceutical compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves,
10 vascular grafts, stents and catheters. Vascular stents, for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury). However, patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted
15 effects may be prevented or mitigated by pre-coating the device with a composition comprising a kinase inhibitor. Suitable coatings and the general preparation of coated implantable devices are described in US Patents
6,099,562; 5,886,026; and 5,304,121. The coatings are
20 typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may
optionally be further covered by a suitable topcoat of
25 fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition. Implantable devices coated with a kinase inhibitor of
this invention are another embodiment of the present
30 invention.

According to another embodiment, the invention provides methods for treating or preventing an ERK- or AKT-mediated condition comprising the step of administering to a patient one of the above-described

pharmaceutical compositions. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.

Preferably, that method is used to treat or
5 prevent a condition selected from cancers such as cancers of the breast, colon, prostate, skin, pancreas, brain, genitourinary tract, lymphatic system, stomach, larynx and lung, including lung adenocarcinoma and small cell lung cancer, stroke, diabetes, hepatomegaly,
10 cardiomegaly, Alzheimer's disease, cystic fibrosis, and viral disease, or any specific disease or disorder described above.

Depending upon the particular ERK- or AKT-mediated condition to be treated or prevented, additional
15 therapeutic agents, which are normally administered to treat or prevent that condition, may be administered together with the ERK or AKT inhibitors of this invention. For example, chemotherapeutic agents or other anti-proliferative agents may be combined with the
20 inhibitors of this invention to treat proliferative diseases and cancer. Examples of known chemotherapeutic agents include, but are not limited to, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum
25 derivatives.

Other examples of therapeutic agents the inhibitors of this invention may also be combined with include, without limitation, anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA,
30 azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophosphamide, azathioprine, and sulfasalazine; neurotrophic factors

such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; agents for treating diabetes such as insulin, insulin analogues, alpha glucosidase inhibitors, biguanides, and insulin sensitizers; and agents for treating immunodeficiency disorders such as gamma globulin.

These additional therapeutic agents may be administered separately, as part of a multiple dosage regimen, from the kinase inhibitor-containing composition. Alternatively, these agents may be part of a single dosage form, mixed together with the inhibitor in a single composition.

In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

EXAMPLES

Example 1

Compounds of formula II-A were prepared in the following manner in parallel fashion, as shown in Scheme I depicted above. In step (a), a series of separate Friedel-Crafts intermediates 2 were prepared from 2-trichloroacetyl pyrrole (1) by treating a concentrated solution of the pyrrole (1 equivalent) and the

appropriate acyl chloride (1 equivalent) with AlCl_3 (1 equivalent) in minimal dichloroethane at 25°C . After 1 hour, the resulting slurry was purified by silica gel chromatography to afford compounds of formula 2.

5 In step (b), each compound 2 was first dissolved in DMF. A separate solution of 1.2 equivalents of each of six amines 3 in DMF was also prepared. Using a Bohden parallel synthesizer, each compound 2 was treated with each amine 3. The reactions were performed
10 at ambient temperature for 24 hours then concentrated in vacuo to afford compounds of formula 4.

 In step (c), the concentrates of compound 4 were dissolved in THF. Using the Bohden parallel synthesizer, each compound 4 was then treated with a
15 solution of $(\text{Me}_2\text{N})_2\text{CH-O-t-Bu}$ (10 equivalents) in THF. The resulting mixtures were again stirred at ambient temperature for 48 hours then concentrated in vacuo to afford compounds of formula 5.

 In step (d), the concentrates of compound 5
20 were first dissolved in ethanol. Using the Bohden parallel synthesizer, each compound 5 was treated with K_2CO_3 (2 equivalents) and $\text{H}_2\text{NOH}\cdot\text{HCl}$ (2.0 equivalents). The resulting mixtures were stirred at reflux for 12 hours then concentrated in vacuo to afford compounds of
25 formula 6.

 Each compound was purified by preparatory HPLC (Gilson) on a C18 reverse-phase column eluted with a gradient of 10-90% MeCN (0.1% TFA) in water over 15 minutes. The characterization data for these compounds
30 is summarized in Table 5 below and includes LC/MS, HPLC, and ^1H NMR data.

 Unless otherwise indicated, the HPLC method used for the determination of retention time is as follows: on a YMC ODS-AQ 55 120A column with a size of

3.0 x 150 mm, a gradient of water:MeCN, 0.1% TFA (95:5 → 0:100) was run over 15 minutes at 1 mL/min and 214 nm.

As used herein, the term " R_t " refers to the retention time, in minutes, obtained for the compound using the HPLC method as indicated.

Where applicable, ^1H NMR data is also summarized in Table 5 below wherein "Y" designates ^1H NMR data is available and was found to be consistent with structure. Compound numbers correspond to the compound numbers listed in Table 1.

Table 5. Characterization Data for Selected Compounds

Compound No IIA-	M+1	M-1	HPLC Purity (%)	R_t (min)	^1H NMR
1	282		100	8.6	Y
3	358	356	75	9.61	-
6	363	361	100	-	-
15	381	379	93	-	-
16	381	379	100	-	-
17	381	379	100	-	-
23	374	372	100	-	-
24	374	372	100	-	-
29	425	423	98	-	-
30	401	399	100	-	-
31	401	399	98	-	-
32	401	399	100	-	-
36	354	352	96	-	-
37	384	-	90	-	-
38	360	358	100	-	-
39	360	358	75	-	-
42	355	354	100	-	-
43	365	363	100	-	-
44	397	-	92	-	-
45	373	371	100	-	-
46	373	371	100	-	-
47	354	352	85	7.92	Y
48	379	377	84	7.96	-

Compound No IIA-	M+1	M-1	HPLC Purity (%)	R _t (min)	¹ H NMR
49	372	370	90	9.82	-
50	399	397	87	8.37	-
51	371	369	83	7.56	-
52	379	377	100	8.02	-
53	379	377	100	7.83	-
54	372	370	95	9.91	-
55	399	397	95	8.44	-
56	358	356	73	9.64	-
57	371	369	83	7.66	-
58	413	411	93	8.6	-
59	433	431	100	9.09	-
60	392	390	74	10.35	-
61	405	403	70	8.26	-
62	397	395	100	7.99	-
63	397	395	100	7.098	-
64	390	388	100	9.75	-
65	417	415	89	8.42	-
66	-	-	86	9.54	-
67	389	387	68	7.67	-
68	-	-	89	8.1	-
69	-	-	100	8.13	-
70	390	-	81	10.01	-
71	417	415	100	8.56	-
72	376	374	96	9.75	-
73	389	387	62	7.78	-
74	405	403	97	6.9	-
75	405	403	93	6.9	-
76	398	396	85	8.43	-
77	425	423	100	7.27	-
78	384	382	83	8.1	-
79	397	395	98	6.59	-
80	389	387	100	7.29	-
81	389	387	100	7.29	-
82	382	380	100	8.91	-
83	409	407	100	7.7	-
84	368	-	88	8.65	-

Compound No IIA-	M+1	M-1	HPLC Purity (%)	R _t (min)	¹ H NMR
85	381	379	80	6.97	-
86	413	411	100	8.69	-
87	413	411	100	8.67	-
88	406	404	72	10.84	-
89	433	431	100	9.13	-
90	392	390	72	10.54	-
91	405	403	74	8.26	-
92	-	-	92	-	Y
93	358	356	100	-	Y

Example 2

ERK Inhibition Assay:

Compounds were assayed for the inhibition of
 5 ERK2 by a spectrophotometric coupled-enzyme assay. (Fox et
 al (1998) *Protein Sci* 7, 2249). In this assay, a fixed
 concentration of activated ERK2 (10 nM) was incubated
 with various concentrations of the compound in DMSO (2.5
 %) for 10 min. at 30°C in 0.1 M HEPES buffer, pH 7.5,
 10 containing 10 mM MgCl₂, 2.5 mM phosphoenolpyruvate, 200
 μM NADH, 150 μg/mL pyruvate kinase, 50 μg/mL lactate
 dehydrogenase, and 200 μM erktide peptide. The reaction
 was initiated by the addition of 65 μM ATP and the rate
 of decrease of absorbance at 340 nM was monitored. The
 15 percent inhibition values were determined at an inhibitor
 concentration of 10 μM.

Table 6 shows the results of the activity of
 selected compounds of this invention in the ERK2
 inhibition assay. The compound numbers correspond to the
 20 compound numbers in Table 1. Compounds having an
 activity designated as "A" provided a percent inhibition
 value above 60%; compounds having an activity designated
 as "B" provided a percent inhibition value between 30 and

60%; and compounds having an activity designated as "C" provided a percent inhibition value less than 30%.

Table 6. ERK2 Inhibitory Activity of Selected Compounds

No.	Activity	No.	Activity
IIA-1	B	IIA-3	B
IIA-4	C	IIA-5	B
IIA-6	C	IIA-7	C
IIA-8	A	IIA-9	A
IIA-10	A	IIA-11	B
IIA-12	B	IIA-13	B
IIA-15	B	IIA-16	B
IIA-17	B	IIA-18	C
IIA-19	B	IIA-20	B
IIA-22	C	IIA-23	B
IIA-24	A	IIA-25	C
IIA-26	C	IIA-27	C
IIA-28	C	IIA-29	C
IIA-36	B	IIA-37	C
IIA-38	B	IIA-39	B
IIA-40	C	IIA-41	C
IIA-42	C	IIA-43	C
IIA-44	C	IIA-45	C
IIA-46	C	IIA-47	A
IIA-48	A	IIA-49	B
IIA-50	C	IIA-51	C
IIA-52	A	IIA-53	B
IIA-54	C	IIA-55	C
IIA-56	C	IIA-57	C
IIA-58	B	IIA-59	C
IIA-60	B	IIA-61	C
IIA-62	A	IIA-63	A
IIA-64	B	IIA-65	C
IIA-66	B	IIA-67	C
IIA-68	A	IIA-69	B
IIA-70	B	IIA-71	C
IIA-72	B	IIA-73	C
IIA-74	B	IIA-80	B

No.	Activity	No.	Activity
ПА-81	B	ПА-82	B
ПА-84	C	ПА-86	A
ПА-87	B	ПА-88	B
ПА-90	C	ПА-91	C
ПА-106	B	ПА-107	B
ПА-108	B	ПА-109	B
ПА-110	B	ПА-111	B
ПА-112	A	ПА-113	B
ПА-114	A	ПА-115	B
ПА-116	B	ПА-117	C
ПА-118	C	ПА-119	B
ПА-120	A	ПА-121	B
ПА-122	C	ПА-123	C
ПА-124	C	ПА-125	C
ПА-126	B	ПА-127	B
ПА-130	B	ПА-131	C
ПА-132	C	ПА-133	B
ПА-134	A	ПА-135	C
ПА-136	C	ПА-137	C
ПА-138	C	ПА-139	C
ПА-140	B	ПА-141	C
ПА-142	C	ПА-143	A
ПА-144	A	ПА-145	B
ПА-146	B	ПА-147	B
ПА-148	B	ПА-149	C
ПА-150	B	ПА-151	B
ПА-152	C	ПА-153	C
ПА-155	B	ПА-156	C
ПА-157	C	ПА-158	B
ПА-159	C	ПА-160	B
ПА-161	C	ПА-162	C
ПА-164	C	ПА-165	C
ПА-166	C	ПА-167	B
ПА-171	A	ПА-172	B
ПА-173	C	ПА-174	C
ПА-175	A	ПА-176	C
ПА-177	C	ПА-178	C

No.	Activity	No.	Activity
IIA-179	C	IIA-180	C
IIA-181	C	IIA-182	B
IIA-183	B	IIA-184	C
IIA-185	C	IIA-186	C
IIA-187	C	IIA-188	C
IIA-189	B	IIA-190	C
IIA-191	C	-	-

Example 3

AKT3 Inhibition Assay:

Compounds were screened for their ability to
5 inhibit AKT3 using a standard coupled enzyme assay (Fox
et al., Protein Sci., (1998) 7, 2249). Assays were
carried out in a mixture of 100 mM HEPES 7.5, 10 mM
MgCl₂, 25 mM NaCl, 1 mM DTT and 1.5% DMSO. Final
substrate concentrations in the assay were 170 μ M ATP
10 (Sigma Chemicals) and 200 μ M peptide (RPRAATF, American
Peptide, Sunnyvale, CA). Assays were carried out at 30°C
and 45 nM AKT3. Final concentrations of the components
of the coupled enzyme system were 2.5 mM
phosphoenolpyruvate, 300 μ M NADH, 30 μ g/mL pyruvate
15 kinase and 10 μ g/ml lactate dehydrogenase.

An assay stock buffer solution was prepared
containing all of the reagents listed above, with the
exception of AKT3, DTT, and the test compound of
interest. 56 μ l of the stock solution was placed in a
20 384 well plate followed by addition of 1 μ l of 2 mM DMSO
stock containing the test compound (final compound
concentration 30 μ M). The plate was preincubated for
about 10 minutes at 30°C and the reaction initiated by
addition of 10 μ l of enzyme (final concentration 45 nM)
25 and 1 mM DTT. Rates of reaction were obtained using a
BioRad Ultramark plate reader (Hercules, CA) over a 5
minute read time at 30°C.

Table 7 shows the results of the activity of selected compounds of this invention in the AKT3 inhibition assay. The compound numbers correspond to the compound numbers in Table 1. Compounds having an activity designated as "A" provided a percent inhibition value above 30%; compounds having an activity designated as "B" provided a percent inhibition value between 20 and 30%; and compounds having an activity designated as "C" provided a percent inhibition value less than 20%. All percent inhibition values were determined at a 30 μ M inhibitor concentration.

Table 7. AKT3 Inhibitory Activity of Selected Compounds


No.	Activity	No.	Activity
ПА-106	B	ПА-107	A
ПА-108	B	ПА-109	A
ПА-110	B	ПА-111	B
ПА-112	B	ПА-113	B
ПА-114	A	ПА-115	B
ПА-116	A	ПА-117	A
ПА-118	A	ПА-119	A
ПА-120	A	ПА-121	C
ПА-122	A	ПА-123	A
ПА-124	C	ПА-125	C
ПА-126	B	ПА-127	B
ПА-131	C	ПА-132	B
ПА-133	C	ПА-134	C
ПА-135	C	ПА-136	C
ПА-139	C	ПА-140	C
ПА-141	C	ПА-142	C
ПА-143	A	ПА-144	C
ПА-145	C	ПА-146	C
ПА-147	C	ПА-148	C
ПА-150	C	ПА-151	B
ПА-153	A	ПА-155	C
ПА-156	C	ПА-159	C

No.	Activity	No.	Activity
IIA-160	C	IIA-161	C
IIA-162	C	IIA-163	A
IIA-164	A	IIA-165	C
IIA-166	C	IIA-167	C
IIA-171	C	IIA-172	B
IIA-173	B	IIA-174	C
IIA-175	C	IIA-176	C
IIA-177	C	IIA-178	C
IIA-179	C	IIA-180	A
IIA-181	C	IIA-182	B
IIA-183	C	IIA-184	C
IIA-185	C	IIA-186	C
IIA-187	C	IIA-188	C
IIA-189	B	-	-

While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments which have been represented by way of example.

We Claim:

1. A compound of formula I:



I

or a pharmaceutically acceptable derivative or prodrug thereof, wherein:

Ht is a heteroaryl ring selected from pyrrol-3-yl, pyrazol-3-yl, [1,2,4]triazol-3-yl, [1,2,3]triazol-4-yl, or tetrazol-5-yl; said pyrrol-3-yl and pyrazol-3-yl each having R^3 and QR^4 substituents, and said triazole substituted by either R^3 or QR^4 ;

A-B is N-O or O-N;

R^1 is selected from R^5 , fluorine, $N(R^5)_2$, OR, $NRCOR$, $CON(R^5)_2$, SO_2R , $NRSO_2R$, or $SO_2N(R^5)_2$;

T and Q are each independently selected from a valence bond or a linker group;

each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons;

R^2 is selected from hydrogen, CN, fluorine, or an optionally substituted group selected from aryl, heteroaryl, heterocyclyl, an acyclic aliphatic group having one to six carbons, or a cyclic aliphatic group having four to ten carbons; wherein R^2 has up to one L-W substituent and up to three R^8 substituents;

L is a C_{1-6} alkylidene chain which is optionally substituted, and wherein up to two methylene units of L are optionally replaced by $-C(O)-$, $-C(O)C(O)-$, $-CONH-$,

-CONHNH-, -CO₂-, -OC(O)-, -NHCO₂-, -O-, -NHCONH-,
 -OC(O)NH-, -NHNH-, -NHCO-, -S-, -SO-, -SO₂-, -NH-,
 -SO₂NH-, -NHSO₂NH-, or -NHSO₂-;

W is selected from R⁹, CH(R⁹)₂, CH(R⁹)N(R⁹)₂, or N(R⁹)₂;

R³ is selected from R, OH, OR, N(R)₂, fluorine, or CN;

R⁴ is selected from -R⁶, -NH₂, -NHR⁶, -N(R⁶)₂, or
 -NR⁶(CH₂)_yN(R⁶)₂;

each R⁵ is independently selected from hydrogen or an
 optionally substituted aliphatic group having one to
 six carbons or two R⁵ on the same nitrogen may be taken
 together with the nitrogen to form a four to eight
 membered ring having one to three heteroatoms;

each R⁶ is independently selected from R⁵, -(CH₂)_yCH(R⁷)₂,
 or -(CH₂)_yR⁷;

y is 0-6;

each R⁷ is an optionally substituted group independently
 selected from R, aryl, aralkyl, aralkoxy, heteroaryl,
 heteroarylalkyl, heteroarylalkoxy, heterocyclyl,
 heterocyclylalkyl, heterocyclylalkoxy, hydroxyalkyl,
 alkoxyalkyl, aryloxyalkyl, or alkoxycarbonyl;


each R⁸ is independently selected from halogen, -R', -OR',
 -SR', -NO₂, -CN, -N(R⁵)₂, -NRC(O)R', -NRC(O)N(R⁵)₂,
 -NRNRCO₂R', -NRNRC(O)R', -NRNRC(O)N(R⁵)₂, -NRNRCO₂R',
 -C(O)C(O)R', -C(O)CH₂C(O)R', -CO₂R', -C(O)R',
 -C(O)N(R⁵)₂, -OC(O)N(R⁵)₂, -S(O)₂R', -SO₂N(R⁵)₂, -S(O)R',
 -NRSO₂N(R⁵)₂, -NRSO₂R', -C(=S)N(R⁵)₂, or -C(=NH)N(R⁵)₂;

wherein each R' is independently selected from
 hydrogen, or an optionally substituted group selected
 from aliphatic, heteroaryl, heterocyclyl, or phenyl;
 and

each R⁹ is independently selected from R⁵, R⁸, or an
 optionally substituted group selected from aryl,
 aralkyl, aralkoxy, heteroaryl, heteroaralkyl,
 heterocyclyl, or heterocyclylalkyl; provided that when

Ht is a pyrazole ring, R^1 is methyl in the 5-position, and $T-R^2$ is H in the 4-position, then Ht is other than 3-ethoxycarbonylpyrazol-5-yl; when R^1 , R^3 and $Q-R^4$ are all H, then $T-R^2$ is other than phenyl; and when R^3 is methyl in the 5 position, $Q-R^4$ is other than $C(O)OMe$ in the 4 position.


2. The compound according to claim 1 having the formula:



II

or a pharmaceutically acceptable derivative or prodrug thereof.

3. The compound according to claim 2 having the formula:



II-A

or a pharmaceutically acceptable derivative or prodrug thereof.

4. The compound according to claim 3, wherein said compound has one or more features selected from the group consisting of:


- (a) Q is $-CO-$, $-CO_2-$, or $-CONH-$;
- (b) T is a valence bond, $-NHC(O)-$, or $-NHCH_2-$;
- (c) R^1 is hydrogen or NHR ;

- (d) R^2 is an optionally substituted aryl ring having up to one L-W substituent and up to three R^8 substituents;
- (e) W is selected from R^9 , $CH(R^9)_2$, $CH(R^9)N(R^9)_2$, or $N(R^9)_2$;
- (f) R^3 is hydrogen;
- (g) R^4 is selected from $-R^6$, $-NH_2$, $-NHR^6$, $-N(R^6)_2$, or $-NR^6(CH_2)_yN(R^6)_2$;
- (h) R^6 is R^5 , $-(CH_2)_yCH(R^7)_2$, or $-(CH_2)_yR^7$; and
- (i) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl.

5. The compound according to claim 4, wherein:

- (a) Q is $-CO-$, $-CO_2-$, or $-CONH-$;
- (b) T is a valence bond, $-NHC(O)-$, or $-NHCH_2-$;
- (c) R^1 is hydrogen or NHR ;
- (d) R^2 is an optionally substituted aryl ring having up to one L-W substituent and up to three R^8 substituents;
- (e) W is selected from R^9 , $CH(R^9)_2$, $CH(R^9)N(R^9)_2$, or $N(R^9)_2$;
- (f) R^3 is hydrogen;
- (g) R^4 is selected from $-R^6$, $-NH_2$, $-NHR^6$, $-N(R^6)_2$, or $-NR^6(CH_2)_yN(R^6)_2$;
- (h) R^6 is R^5 , $-(CH_2)_yCH(R^7)_2$, or $-(CH_2)_yR^7$; and
- (i) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl.


6. The compound according to claim 1 having the formula:



III

or a pharmaceutically acceptable derivative or prodrug thereof.

7. The compound according to claim 6 having the formula:



III-A

or a pharmaceutically acceptable derivative or prodrug thereof.

8. The compound according to claim 7, wherein said compound has one or more features selected from the group consisting of:


- (a) Q is -CO-, -CO₂-, or -CONH-;
- (b) T is a valence bond, -NHC(O)-, or -NHCH₂-;
- (c) R¹ is hydrogen or NHR;
- (d) R² is an optionally substituted aryl ring having up to one L-W substituent and up to three R⁸ substituents;
- (e) W is selected from R⁹, CH(R⁹)₂, CH(R⁹)N(R⁹)₂, or N(R⁹)₂;
- (f) R³ is hydrogen;
- (g) R⁴ is selected from -R⁶, -NH₂, -NHR⁶, -N(R⁶)₂, or -NR⁶(CH₂)ᵧN(R⁶)₂;
- (h) R⁶ is R⁵, -(CH₂)ᵧCH(R⁷)₂, or -(CH₂)ᵧR⁷; and

- (i) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl.

9. The compound according to claim 8, wherein:

- (a) Q is $-\text{CO}-$, $-\text{CO}_2-$, or $-\text{CONH}-$;
- (b) T is a valence bond, $-\text{NHC(O)}-$, or $-\text{NHCH}_2-$;
- (c) R^1 is hydrogen or NHR ;
- (d) R^2 is an optionally substituted aryl ring having up to one L-W substituent and up to three R^8 substituents;
- (e) W is selected from R^9 , $\text{CH}(R^9)_2$, $\text{CH}(R^9)\text{N}(R^9)_2$, or $\text{N}(R^9)_2$;
- (f) R^3 is hydrogen;
- (g) R^4 is selected from $-\text{R}^6$, $-\text{NH}_2$, $-\text{NHR}^6$, $-\text{N}(\text{R}^6)_2$, or $-\text{NR}^6(\text{CH}_2)_y\text{N}(\text{R}^6)_2$;
- (h) R^6 is R^5 , $-(\text{CH}_2)_y\text{CH}(\text{R}^7)_2$, or $-(\text{CH}_2)_y\text{R}^7$; and
- (i) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl.


10. The compound according to claim 1 having the formula:



IV

or a pharmaceutically acceptable derivative or prodrug thereof.

11. The compound according to claim 10 having the formula:



IV-A

or a pharmaceutically acceptable derivative or prodrug thereof.

12. The compound according to claim 11, wherein said compound has one or more features selected from the group consisting of:


- (a) Q is -CO-, -CO₂-, or -CONH-;
- (b) T is a valence bond, -NHC(O)-, or -NHCH₂-;
- (c) R² is an optionally substituted aryl ring having up to one L-W substituent and up to three R⁸ substituents;
- (d) R³ is hydrogen;
- (e) R⁴ is selected from -R⁶, -NH₂, -NHR⁶, -N(R⁶)₂, or -NR⁶(CH₂)_yN(R⁶)₂;
- (f) R⁶ is R⁵, -(CH₂)_yCH(R⁷)₂, or -(CH₂)_yR⁷; and
- (g) R⁷ is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group.

13. The compound according to claim 12, wherein:

- (a) Q is -CO-, -CO₂-, or -CONH-;
- (b) T is a valence bond, -NHC(O)-, or -NHCH₂-;
- (c) R² is an optionally substituted aryl ring having up to one L-W substituent and up to three R⁸ substituents;
- (d) R³ is hydrogen;
- (e) R⁴ is selected from -R⁶, -NH₂, -NHR⁶, -N(R⁶)₂, or -NR⁶(CH₂)_yN(R⁶)₂;


- (f) R^6 is R^5 , $-(CH_2)_yCH(R^7)_2$, or $-(CH_2)_yR^7$; and
 (g) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group.

14. The compound according to claim 1 having the formula:



or a pharmaceutically acceptable derivative or prodrug thereof.

15. The compound according to claim 14 having the formula:



or a pharmaceutically acceptable derivative or prodrug thereof.

16. The compound according to claim 15, wherein said compound has one or more features selected from the group consisting of:

- (a) Q is $-CO-$, $-CO_2-$, or $-CONH-$;
 (b) R^1 is hydrogen or NHR ;
 (c) W is selected from R^9 , $CH(R^9)_2$, $CH(R^9)N(R^9)_2$, or $N(R^9)_2$;

- (d) R^3 is hydrogen;
- (e) R^8 is halogen, $-R'$, $-OR'$, $-SR'$, $-NO_2$, $-CN$, or $-N(R^5)_2$;
- (f) R^4 is selected from $-R^6$, $-NH_2$, $-NHR^6$, $-N(R^6)_2$, or $-NR^6(CH_2)_yN(R^6)_2$;
- (g) R^6 is R^5 , $-(CH_2)_yCH(R^7)_2$, or $-(CH_2)_yR^7$; and
- (h) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group.

17. The compound according to claim 16, wherein:

- (a) Q is $-CO-$, $-CO_2-$, or $-CONH-$;
- (b) R^1 is hydrogen or NHR ;
- (c) W is selected from R^9 , $CH(R^9)_2$, $CH(R^9)N(R^9)_2$, or $N(R^9)_2$;
- (d) R^3 is hydrogen;
- (e) R^8 is halogen, $-R'$, $-OR'$, $-SR'$, $-NO_2$, $-CN$, or $-N(R^5)_2$;
- (f) R^4 is selected from $-R^6$, $-NH_2$, $-NHR^6$, $-N(R^6)_2$, or $-NR^6(CH_2)_yN(R^6)_2$;
- (g) R^6 is R^5 , $-(CH_2)_yCH(R^7)_2$, or $-(CH_2)_yR^7$; and
- (h) R^7 is an optionally substituted group selected from aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl group.

18. The compound according to claim 1, wherein said compound is selected from those listed in any of Tables 1-4.

19. A composition comprising a compound according to any one of claims 1-18; and a pharmaceutically acceptable carrier.

20. The composition according to claim 19 wherein said compound is formulated in a pharmaceutically acceptable manner for administration to a patient.

21. The composition according to claim 19 further comprising an additional therapeutic agent.

22. The composition according to claim 20 further comprising an additional therapeutic agent.

23. A method of inhibiting ERK or AKT activity in a biological sample, comprising the step of contacting said biological sample with a compound according to any of claims 1-18.

24. A method for treating an ERK-mediated disease in a patient comprising the step of administering to said patient a composition according to claim 19.

25. A method for treating an ERK-mediated disease in a patient comprising the step of administering to said patient a composition according to claim 20.

26. The method according to claim 25 further comprising the step of administering to said patient an additional therapeutic agent.

27. A method for treating a disease in a patient, wherein said disease is selected from cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders, inflammation, neurological disorders, a hormone-related disease, conditions associated with

organ transplantation, immunodeficiency disorders, destructive bone disorders, proliferative disorders, infectious diseases, conditions associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukemia (CML), liver disease, or pathologic immune conditions involving T cell activation.

28. The method according to claim 27 wherein the disease is cancer.

29. The method according to claim 28 wherein said cancer is selected from breast; ovary; cervix; prostate; testis, genitourinary tract; esophagus; larynx, glioblastoma; neuroblastoma; stomach; skin, keratoacanthoma; lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma; bone; colon, adenoma; pancreas, adenocarcinoma; thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma; seminoma; melanoma; sarcoma; bladder carcinoma; liver carcinoma and biliary passages; kidney carcinoma; myeloid disorders; lymphoid disorders, Hodgkin's, hairy cells; buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx; small intestine; colon-rectum, large intestine, rectum; brain and central nervous system; or leukemia.

30. The method according to either of claims 28 or 29 comprising the additional step of administering to said patient a chemotherapeutic agent.

31. The method according to claim 27 wherein the disease is an autoimmune disease.

32. The method according to claim 31 wherein said autoimmune disease is selected from psoriasis, SLE Lupus,

cystic fibrosis, or conditions associated with organ transplantation.

33. The method according to claim 27 wherein the disease is a neurodegenerative disease.

34. The method according to claim 33 wherein said neurodegenerative disease is selected from Alzheimer's Disease, Parkinson's Disease, ALS, epilepsy and seizures, Huntington's disease, or stroke.

35. The method according to claim 27 wherein the disease is a cardiovascular disease.

36. The method according to claim 35 wherein said cardiovascular disease is selected from restenosis, cardiomegaly, arteriosclerosis, myocardial infarction, or congestive heart failure.

37. The method according to either of claims 35 or 36 comprising the additional step of administering to said patient a therapeutic agent for treating cardiovascular disease.

38. The method according to claim 27 wherein the disease is an inflammatory disease.

39. The method according to claim 38 wherein said inflammatory disease is selected from asthma, rheumatoid arthritis, or atopic dermatitis.

40. The method according to claim 27 wherein the disease is a liver disease.

41. The method according to claim 40 wherein said liver disease is selected from hepatomegaly or hepatic ischemia.

42. A composition for coating an implantable device comprising a compound according to claim 1 and a carrier suitable for coating said implantable device.

43. An implantable device coated with a composition according to claim 42.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/28790

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D413/04 C07D413/14 C07D417/14 A61K31/422 A61K31/433
A61K31/439 A61K31/454 A61K31/4725 A61K31/496 A61K31/497
A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; Database accession no. 1996:298380 XP002186557 RN 176593-91-2 & JP 08 027130 A (TEIKOKU HORMONE MFG CO LTD) 30 January 1996 (1996-01-30) ---	1-4, 19, 20
X	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Foerderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 18814 (BRN) XP002186558 abstract & GAZZ. CHIM. ITAL., vol. 79, 1949, page 683, 685, 687, 688 --- -/-	1, 2

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

3 January 2002

Date of mailing of the international search report

22/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

 Int. Application No
 PC1/US 01/28790

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOLLAND G F ET AL: "Heterocyclic tetrazoles, a new class of lipolysis inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, vol. 10, no. 2, 27 February 1967 (1967-02-27), pages 149-154, XP002186552 the whole document, particularly pages 151 and 152, tables II-IV	1,2,6, 19,20
X	ALMERICO A M ET AL: "Polycondensed nitrogen heterocycles. Part 17. Isoxazolo'4,3-d!pyrazolo'3,4-f!'1,2,3-triazepine. A new ring system" JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 24, no. 5, 1987, pages 1309-1311, XP002186553 the whole document	1,6
X	TANAKA Y ET AL: "Syntheses and properties of H-1,2,3-triazoles" TETRAHEDRON, vol. 29, no. 21, November 1973 (1973-11), pages 3271-3283, XP002186554 the whole document, particularly page 3275, compound 5b	1,2
X	BANG-ANDERSEN B ET AL: "Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships" JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 18, 29 August 1997 (1997-08-29), pages 2831-2842, XP002186555 the whole document	1,2,19, 20
X	JONES R A ET AL: "1,3-Dipolar addition reactions with vinylpyrroles" HETEROCYCLES, vol. 14, no. 2, 1980, pages 185-188, XP000999958 the whole document, particularly page 186, table 2, in combination with page 187, last paragraph	1-4
X	AJELLO E ET AL: "New syntheses of condensed heterocycles from isoxazole derivatives. III. s-Triazolo'4,3-b!pyridazines" JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 9, no. 4, 1972, pages 1169-1170, XP000571653 the whole document	1,2

-/-

INTERNATIONAL SEARCH REPORT

International Application No.

PCI/uS 01/28790

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 470 862 A (LIN B-S ET AL) 28 November 1995 (1995-11-28) cited in the application the whole document, particularly columns 19 and 20, formulae XVIIIa and XVIIb, and columns 33 and 34 ---	1,2,19, 20
X	DE 44 38 824 A (SCHERING AG) 20 April 1995 (1995-04-20) the whole document, particularly example 3 ---	1,6,19, 20
X	US 5 498 720 A (LEE A-R) 12 March 1996 (1996-03-12) the whole document, particularly columns 7 and 8, compounds 12-15, and columns 40-43, compounds 40-43 ---	1,6,19, 20
X	WO 98 15542 A (H. LUNDBECK A/S) 16 April 1998 (1998-04-16) the whole document, particularly examples 4 and 5 ---	1,2,19, 20
X	WO 98 35944 A (BAYER CORPORATION) 20 August 1998 (1998-08-20) the whole document, particularly page 29, table 1, composition 2, and page 44, table 4, composition 150 ---	1,6,19, 20
P,X	AIELLO E ET AL: "Synthesis and antimicrobial activity of new 3-(1-R-3(5)-methyl-4-nitroso-1H-5(3)- pyrazolyl)-5-methylisoxazoles" BIOORGANIC & MEDICINAL CHEMISTRY, vol. 8, no. 12, December 2000 (2000-12), pages 2719-2728, XP002186556 the whole document ---	1,6,19, 20
P,X	WO 01 57022 A (VERTEX PHARMACEUTICALS INCORPORATED) 9 August 2001 (2001-08-09) the whole document ---	1-43
P,X	WO 01 56557 A (VERTEX PHARMACEUTICALS INCORPORATED) 9 August 2001 (2001-08-09) the whole document ---	1-43
A	DATABASE WPI Section Ch, Week 200031 Derwent Publications Ltd., London, GB; Class B03, AN 2000-353387 XP002186559 & JP 2000 086657 A (TEIKOKU HORMONE MFG CO LTD), 28 March 2000 (2000-03-28) abstract --- -/--	1,23

INTERNATIONAL SEARCH REPORT

International Application No
PC1/US 01/28790

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 61440 A (SMITHKLINE BEECHAM CORPORATION) 2 December 1999 (1999-12-02) the whole document	1,23

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-3, 6, 7, 10, 11, 14, 15 (all partly)

The scope of claims 1-3, 6, 7, 10, 11, 14 and 15, in as far as the expressions "pharmaceutically acceptable derivative" and "prodrug" are concerned, is so unclear (Article 6 PCT) that a meaningful International Search is impossible with regard to these expressions.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/28790

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 8027130	A	30-01-1996	NONE	
US 5470862	A	28-11-1995	NONE	
DE 4438824	A	20-04-1995	DE 4438824 A1	20-04-1995
US 5498720	A	12-03-1996	NONE	
WO 9815542	A	16-04-1998	AU 733004 B2 AU 4451797 A BG 103348 A BR 9712198 A CN 1238766 A CZ 9901168 A3 WO 9815542 A1 EP 0934286 A1 HU 0000084 A2 JP 2001501630 T NO 991561 A PL 332553 A1 SK 42899 A3 TR 9900724 T2 US 6200999 B1	03-05-2001 05-05-1998 30-11-1999 31-08-1999 15-12-1999 15-09-1999 16-04-1998 11-08-1999 28-06-2000 06-02-2001 04-06-1999 13-09-1999 06-08-1999 21-06-1999 13-03-2001
WO 9835944	A	20-08-1998	AU 6267198 A CA 2251580 A1 EP 0927166 A1 JP 2000510870 T WO 9835944 A1	08-09-1998 20-08-1998 07-07-1999 22-08-2000 20-08-1998
WO 0157022	A	09-08-2001	AU 3488801 A AU 3672301 A WO 0156993 A2 WO 0157022 A2	14-08-2001 14-08-2001 09-08-2001 09-08-2001
WO 0156557	A	09-08-2001	AU 3672001 A WO 0156557 A2	14-08-2001 09-08-2001
JP 2000086657	A	28-03-2000	NONE	
WO 9961440	A	02-12-1999	EP 1082320 A1 WO 9961440 A1	14-03-2001 02-12-1999